Synthetic Immune Niches for Cancer Immunotherapy

Nat Rev Immunol. 2018 Mar;18(3):212-219. doi: 10.1038/nri.2017.89. Epub 2017 Aug 30.

Abstract

Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited number of patients who benefit from such treatment, and it can sometimes have severe treatment-associated adverse events. Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity. Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity. In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumour immunity. Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cancer Vaccines / immunology*
  • Humans
  • Immunomodulation / immunology*
  • Immunotherapy, Adoptive / methods*
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Tissue Scaffolds

Substances

  • Cancer Vaccines